Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

329
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
329
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

646
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
646
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

1.4K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.4K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

352
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
352
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids.

Drugs·2017
Same author

Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.

Targeted oncology·2017
Same author

Cariprazine: A Review in Schizophrenia.

CNS drugs·2017
Same author

Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus.

Drugs·2017
Same author

Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.

Drugs·2016
Same author

Oxycodone DETERx<sup>®</sup> ER Capsules: A Review in Severe, Chronic Pain.

Drugs·2016
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Apr 1, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.3K

Cobimetinib: First Global Approval.

Karly P Garnock-Jones1

  • 1Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.

Drugs
|October 11, 2015
PubMed
Summary
This summary is machine-generated.

Cobimetinib, a MEK inhibitor, is approved for advanced BRAF V600 mutation-positive melanoma. This oral medication targets the MAPK/ERK pathway, offering a new treatment option for patients with this specific cancer type.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.7K

Related Experiment Videos

Last Updated: Apr 1, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.3K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.7K

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • The MAPK/ERK signaling pathway is crucial in cell growth and is often over-activated in various cancers.
  • Over-activation of this pathway, specifically the MEK component, drives tumor progression in conditions like melanoma and breast cancer.
  • Targeting the MEK component offers a potential therapeutic strategy for cancers with aberrant MAPK/ERK signaling.

Purpose of the Study:

  • To summarize the key developmental milestones of cobimetinib.
  • To highlight the regulatory approval process and outcomes for cobimetinib.
  • To provide an overview of cobimetinib's journey leading to its first marketing authorization.

Main Methods:

  • Review of preclinical and clinical development data for cobimetinib.
  • Analysis of regulatory submission and review processes.
  • Synthesis of information on cobimetinib's mechanism of action and therapeutic indications.

Main Results:

  • Cobimetinib, an orally available small molecule inhibitor, has been developed.
  • Cobimetinib targets the MEK component of the MAPK/ERK pathway.
  • Cobimetinib received approval in Switzerland in combination with vemurafenib for unresectable or metastatic BRAF V600 mutation-positive melanoma.

Conclusions:

  • Cobimetinib represents a significant advancement in the treatment of BRAF V600 mutation-positive melanoma.
  • The development and approval of cobimetinib demonstrate the successful targeting of the MAPK/ERK pathway.
  • Further regulatory reviews are ongoing in major markets like the USA and EU, indicating broader potential.